Trial Profile
An Exploratory Phase 1B Study to Assess the Effects of Merestinib on Bone Metastases in Subjects With Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Merestinib (Primary)
- Indications Advanced breast cancer; Bone metastases
- Focus Adverse reactions
- 10 Jun 2020 Status changed from recruiting to discontinued.
- 11 Jan 2018 Status changed from not yet recruiting to recruiting.
- 13 Dec 2017 Planned initiation date changed from 1 Nov 2017 to 1 Jan 2018.